0726 GMT - AstraZeneca's shares are valued slightly ahead of its peers, but they remain well below their historical valuations, Shore Capital Markets says. The Anglo-Swedish pharmaceutical company's second-quarter results exceeded expectations, with guidance reiterated. AstraZeneca should be able to deliver on its longer-term growth ambitions, and fair value for the share price should be around 13,500 pence, Shore Capital's Sean Conroy says in a research note. This is a premium to the company's peers, justified given its pipeline momentum, limited exposure to patent expirations this decade and earnings potential, Conroy says. That said, uncertainty stoked by the U.S. political backdrop could continue to weigh on shares and fuel a degree of volatility until better visibility emerges, Conroy adds. Shore retains its buy recommendation. Shares are up 0.8% at 10,878 pence.(joseph.hoppe@wsj.com)

(END) Dow Jones Newswires

July 29, 2025 03:26 ET (07:26 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.